Plasma EDA demonstrated limited clinical utility alone and did not improve the diagnostic accuracy of clinical routine markers (HbA1c and ALT) and established scoring systems (NFS and hepatic steatosis index) for NAFLD or NASH. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.